Exact Mass: 413.38687360000006

Exact Mass Matches: 413.38687360000006

Found 80 metabolites which its exact mass value is equals to given mass value 413.38687360000006, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Heptadecanoyl carnitine

3-Carboxy-N,N,N-trimethyl-2-[(1-oxoheptadecyl)oxy]-1-propanaminium inner salt

C24H47NO4 (413.3504902)


Heptadecanoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Heptadecanoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).

   

11-MethylHexadecanoylcarnitine

3-[(11-methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


11-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-MethylHexadecanoylcarnitine

3-[(4-methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


4-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 4-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

14-MethylHexadecanoylcarnitine

3-[(14-methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


14-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 14-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 14-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 14-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-MethylHexadecanoylcarnitine

3-[(10-Methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C24H47NO4 (413.3504902)


10-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-MethylHexadecanoylcarnitine

3-[(12-methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


12-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 12-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-MethylHexadecanoylcarnitine

3-[(5-methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


5-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-MethylHexadecanoylcarnitine

3-[(8-methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


8-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

13-MethylHexadecanoylcarnitine

3-[(13-Methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C24H47NO4 (413.3504902)


13-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 13-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 13-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 13-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-MethylHexadecanoylcarnitine

3-[(3-Methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C24H47NO4 (413.3504902)


3-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-MethylHexadecanoylcarnitine

3-[(7-methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


7-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-MethylHexadecanoylcarnitine

3-[(9-methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


9-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-MethylHexadecanoylcarnitine

3-[(6-methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


6-MethylHexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-MethylHexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-MethylHexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

15-methylhexadecanoylcarnitine

3-[(15-Methylhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C24H47NO4 (413.3504902)


15-methylhexadecanoylcarnitine is an acylcarnitine. More specifically, it is an 15-methylhexadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 15-methylhexadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 15-methylhexadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   
   
   

(E,E)-3-(7,16-Tricosadienyl)-1H-2-carboxaldehyde

(E,E)-3-(7,16-Tricosadienyl)-1H-2-carboxaldehyde

C28H47NO (413.3657452)


   

Heptadecanoate

3-Carboxy-N,N,N-trimethyl-2-[(1-oxoheptadecyl)oxy]-1-propanaminium inner salt

C24H47NO4 (413.3504902)


   

CAR 17:0

3-(heptadecanoyloxy)-4-(trimethylazaniumyl)butanoate

C24H47NO4 (413.3504902)


   

N-(2-hydroxyethyl)-N,N-dimethyl-3-[(1-oxo-octadecyl)amino]-1-propanaminium

N-(2-hydroxyethyl)-N,N-dimethyl-3-[(1-oxo-octadecyl)amino]-1-propanaminium

C25H53N2O2+ (413.41068179999996)


   

2-(Bis(2-hydroxyethyl)amino)ethyl oleate

2-(Bis(2-hydroxyethyl)amino)ethyl oleate

C24H47NO4 (413.3504902)


   

(2S,3R,4E)-2-amino-3-(tert-butyldimethylsilyloxy)-4-octadecene-1-ol

(2S,3R,4E)-2-amino-3-(tert-butyldimethylsilyloxy)-4-octadecene-1-ol

C24H51NO2Si (413.3688866)


   

(4E,8E,12Z,16Z)-N,N,4,8,13,17,21-Heptamethyldocosa-4,8,12,16,20-pentaen-1-amine

(4E,8E,12Z,16Z)-N,N,4,8,13,17,21-Heptamethyldocosa-4,8,12,16,20-pentaen-1-amine

C29H51N (413.4021286)


   

25-Azacycloartenol

25-Azacycloartenol

C29H51N (413.4021286)


   

4-MethylHexadecanoylcarnitine

4-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

5-MethylHexadecanoylcarnitine

5-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

8-MethylHexadecanoylcarnitine

8-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

3-MethylHexadecanoylcarnitine

3-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

7-MethylHexadecanoylcarnitine

7-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

9-MethylHexadecanoylcarnitine

9-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

6-MethylHexadecanoylcarnitine

6-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

11-MethylHexadecanoylcarnitine

11-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

14-MethylHexadecanoylcarnitine

14-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

10-MethylHexadecanoylcarnitine

10-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

12-MethylHexadecanoylcarnitine

12-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

13-MethylHexadecanoylcarnitine

13-MethylHexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

N-(2-hydroxyhexanoyl)sphingosine

N-(2-hydroxyhexanoyl)sphingosine

C24H47NO4 (413.3504902)


A 2-N-(2-hydroxyacyl)sphingosine in which the ceramide N-acyl group is specified as 2-hydroxyhexanoyl.

   

(13Z,16Z,19Z,22Z,25Z)-octacosapentaenoate

(13Z,16Z,19Z,22Z,25Z)-octacosapentaenoate

C28H45O2- (413.341937)


A polyunsaturated fatty acid anion that is the conjugate base of (13Z,16Z,19Z,22Z,25Z)-octacosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(10Z,13Z,16Z,19Z,22Z)-octacosapentaenoate

(10Z,13Z,16Z,19Z,22Z)-octacosapentaenoate

C28H45O2- (413.341937)


A polyunsaturated fatty acid anion that is the conjugate base of (10Z,13Z,16Z,19Z,22Z)-octacosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

N-(1,3-dihydroxyoctadecan-2-yl)heptanamide

N-(1,3-dihydroxyoctadecan-2-yl)heptanamide

C25H51NO3 (413.38687360000006)


   

2-Aminohexacosane-1,3-diol

2-Aminohexacosane-1,3-diol

C26H55NO2 (413.423257)


   

N-(1,3-dihydroxyicosan-2-yl)pentanamide

N-(1,3-dihydroxyicosan-2-yl)pentanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxynonadecan-2-yl)hexanamide

N-(1,3-dihydroxynonadecan-2-yl)hexanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxydocosan-2-yl)propanamide

N-(1,3-dihydroxydocosan-2-yl)propanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxynonan-2-yl)hexadecanamide

N-(1,3-dihydroxynonan-2-yl)hexadecanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxyheptadecan-2-yl)octanamide

N-(1,3-dihydroxyheptadecan-2-yl)octanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxyoctan-2-yl)heptadecanamide

N-(1,3-dihydroxyoctan-2-yl)heptadecanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxytricosan-2-yl)acetamide

N-(1,3-dihydroxytricosan-2-yl)acetamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxyhenicosan-2-yl)butanamide

N-(1,3-dihydroxyhenicosan-2-yl)butanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxyhexadecan-2-yl)nonanamide

N-(1,3-dihydroxyhexadecan-2-yl)nonanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxypentadecan-2-yl)decanamide

N-(1,3-dihydroxypentadecan-2-yl)decanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxydodecan-2-yl)tridecanamide

N-(1,3-dihydroxydodecan-2-yl)tridecanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxyundecan-2-yl)tetradecanamide

N-(1,3-dihydroxyundecan-2-yl)tetradecanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxydecan-2-yl)pentadecanamide

N-(1,3-dihydroxydecan-2-yl)pentadecanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxytetradecan-2-yl)undecanamide

N-(1,3-dihydroxytetradecan-2-yl)undecanamide

C25H51NO3 (413.38687360000006)


   

N-(1,3-dihydroxytridecan-2-yl)dodecanamide

N-(1,3-dihydroxytridecan-2-yl)dodecanamide

C25H51NO3 (413.38687360000006)


   

N-(decanoyl)-pentadecasphinganine

N-(decanoyl)-pentadecasphinganine

C25H51NO3 (413.38687360000006)


   

O-heptadecanoylcarnitine

O-heptadecanoylcarnitine

C24H47NO4 (413.3504902)


An O-acylcarnitine in which the acyl group is specified as heptadecanoyl.

   

15-methylhexadecanoylcarnitine

15-methylhexadecanoylcarnitine

C24H47NO4 (413.3504902)


   

octacosapentaenoate

octacosapentaenoate

C28H45O2 (413.341937)


A polyunsaturated fatty acid anion that is the conjugate base of octacosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3. Formula is C28H45O2

   
   
   

Cer 14:1;O2/10:0;2OH

Cer 14:1;O2/10:0;2OH

C24H47NO4 (413.3504902)


   

Cer 14:1;O2/10:0;3OH

Cer 14:1;O2/10:0;3OH

C24H47NO4 (413.3504902)


   
   
   
   
   
   

3-imino-4a,6a,9,9,12a,14a-hexamethyl-1h,2h,4h,5h,6h,7h,8h,8ah,10h,11h,12h,13h,14h,14bh-phenanthro[2,1-f]quinazolin-13-ol

3-imino-4a,6a,9,9,12a,14a-hexamethyl-1h,2h,4h,5h,6h,7h,8h,8ah,10h,11h,12h,13h,14h,14bh-phenanthro[2,1-f]quinazolin-13-ol

C26H43N3O (413.3405948)


   

1-(5,6-dimethylheptan-2-yl)-10a,12a-dimethyl-1h,2h,3h,5h,6h,6ah,7h,8h,9h,10h,11h,12h-naphtho[1,2-h]quinolin-8-ol

1-(5,6-dimethylheptan-2-yl)-10a,12a-dimethyl-1h,2h,3h,5h,6h,6ah,7h,8h,9h,10h,11h,12h-naphtho[1,2-h]quinolin-8-ol

C28H47NO (413.3657452)


   

(8s,10as,12ar)-1-[(2r)-5,6-dimethylheptan-2-yl]-10a,12a-dimethyl-1h,2h,3h,5h,6h,6ah,7h,8h,9h,10h,11h,12h-naphtho[1,2-h]quinolin-8-ol

(8s,10as,12ar)-1-[(2r)-5,6-dimethylheptan-2-yl]-10a,12a-dimethyl-1h,2h,3h,5h,6h,6ah,7h,8h,9h,10h,11h,12h-naphtho[1,2-h]quinolin-8-ol

C28H47NO (413.3657452)


   

5-(tricosa-14,17-dien-1-yl)-1h-pyrrole-2-carbaldehyde

5-(tricosa-14,17-dien-1-yl)-1h-pyrrole-2-carbaldehyde

C28H47NO (413.3657452)


   

7-methyl-5-{[8-methyl-6-(piperidin-2-ylmethyl)-octahydro-1h-quinolizin-4-yl]methyl}-1,2,3,4,6,7,8,8a-octahydroquinoline

7-methyl-5-{[8-methyl-6-(piperidin-2-ylmethyl)-octahydro-1h-quinolizin-4-yl]methyl}-1,2,3,4,6,7,8,8a-octahydroquinoline

C27H47N3 (413.3769782)


   

{[(2r,3r)-3-(octanoyloxy)tetradecan-2-yl]amino}acetic acid

{[(2r,3r)-3-(octanoyloxy)tetradecan-2-yl]amino}acetic acid

C24H47NO4 (413.3504902)


   

(7r,8ar)-5-{[(4r,6s,8r,9ar)-8-methyl-6-[(2r)-piperidin-2-ylmethyl]-octahydro-1h-quinolizin-4-yl]methyl}-7-methyl-1,2,3,4,6,7,8,8a-octahydroquinoline

(7r,8ar)-5-{[(4r,6s,8r,9ar)-8-methyl-6-[(2r)-piperidin-2-ylmethyl]-octahydro-1h-quinolizin-4-yl]methyl}-7-methyl-1,2,3,4,6,7,8,8a-octahydroquinoline

C27H47N3 (413.3769782)


   
   

5-[(14z,17z)-tricosa-14,17-dien-1-yl]-1h-pyrrole-2-carbaldehyde

5-[(14z,17z)-tricosa-14,17-dien-1-yl]-1h-pyrrole-2-carbaldehyde

C28H47NO (413.3657452)


   

(4ar,6as,8as,12as,13r,14ar,14bs)-3-imino-4a,6a,9,9,12a,14a-hexamethyl-1h,2h,4h,5h,6h,7h,8h,8ah,10h,11h,12h,13h,14h,14bh-phenanthro[2,1-f]quinazolin-13-ol

(4ar,6as,8as,12as,13r,14ar,14bs)-3-imino-4a,6a,9,9,12a,14a-hexamethyl-1h,2h,4h,5h,6h,7h,8h,8ah,10h,11h,12h,13h,14h,14bh-phenanthro[2,1-f]quinazolin-13-ol

C26H43N3O (413.3405948)